The Boeing Company and the Boeing Employee Community Fund Board of Alabama are committing $100,000 to support a collaborative kidney cancer research project between HudsonAlpha Institute for Biotechnology and University of Alabama at Birmingham (UAB).
Over the years, Boeing has demonstrated a long-standing commitment to community giving and wellness. The company reaffirmed its commitment earlier this year when Boeing CEO Dennis Muilenburg (who also served as the American Cancer Society’s National Gala Chairman) announced his commitment to provide a company match to contributions made to ACS.
In 2014, HudsonAlpha scientists identified biomarkers that are strong predictors of kidney cancer. In 2016, collaborators at HudsonAlpha and UAB also identified changes to the genome associated with kidney cancer tumors. Brittany Lasseigne, PhD, in the Myers Lab at HudsonAlpha, is performing experiments on kidney cancer samples to identify biomarkers for clinical use. Their research could lead to finding potential new molecules to target for treatment and detection of kidney cancer.
“HudsonAlpha, one of the top genetic sequencing centers in the nation, and UAB, a premier medical research institution, can together change the standard of care for cancer patients by diagnosing patients earlier and using the right treatment for the right person at the right time,” said Richard Myers, PhD, HudsonAlpha faculty investigator, president and science director. “Boeing’s support will be instrumental in making significant advances in cancer research by saving lives through earlier disease diagnosis and treatment options.”
Boeing’s Employee Community Fund Board of Alabama and The Boeing Company have set a wonderful standard for community engagement, and their gift will make a great impact. Corporate gifts are integral to the projects and research at HudsonAlpha. For more information on how your company can be involved, visit www.hudsonalpha.org/corporate-giving-and-sponsorships.